APGO automated insulin delivery with the TouchCare Nano patch pump for adults with type 1 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The RENEW study is a prospective interventional trial of the Medtrum TouchCare Nano patch pump running the APGO automated insulin delivery algorithm in real-world conditions. Adults with type 1 diabetes for at least one year who are 18 or older and able to give informed consent will use the device while researchers record glucose metrics, insulin delivery data, and adverse events. Key exclusions include pregnancy or lactation, severe noncompliance, and use of medications that affect carbohydrate metabolism. The study is conducted at the 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague to provide practical safety and effectiveness data for this patch-pump AID system.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients with T1D
* type 1 diabetes for ≥1 years
* ≥ 18 years old
* written informed consent prior to starting study related activity

Exclusion Criteria:

* severe noncompliance
* lactation, pregnancy, intending to become pregnant during study
* use of medication with effects on carbohydrate metabolism

Where it's running

• 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czechia
  Prague, Czechia Recruiting

Study contacts

• Study coordinator: Jan Soupal
• Email: jan.soupal@seznam.cz
• Phone: +420775654343

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes

  This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.

  Recruiting Fidam Rdc · Bad Mergentheim, Baden-Wurttemberg · NCT07814508

• Tirzepatide for type 1 diabetes patients who are overweight or obese

  This study tests whether tirzepatide can affect stomach emptying in adults with type 1 diabetes and overweight or obesity.

  Recruiting Phase 1 Eli Lilly and Company · Miami, Florida · NCT07803744

• Oral insulin vs. subcutaneous insulin in adults with type 1 diabetes

  This study tests an oral insulin tablet (SCD0503) against subcutaneous insulin and placebo to see how it behaves in the blood and helps control blood sugar in adults with type 1 diabetes.

  Recruiting Phase 1 Sam Chun Dang Pharm. Co. Ltd. · Neuss, North Rhine-Westphalia · NCT07634770

• Genetic risk score and progression to insulin in type 1 diabetes

  This study tests whether a genetic risk score can predict which people with type 1 diabetes will need insulin progression over three years.

  Recruiting Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT07621445

• Home-based use of an advanced hybrid closed-loop insulin pump with telemonitoring for adults with type 1 diabetes

  This study tests whether starting an advanced hybrid closed-loop insulin pump at home, with online education and telemonitoring, is feasible and safe for adults with type 1 diabetes.

  Recruiting Air Liquide Healthcare Spain · Cartagena, Murcia and 2 other locations · NCT07492992

• Diabetes multimorbidity and a voice diary app to help self-manage

  This study tests whether the Fabla-diabetesMM audio diary app is feasible and helpful for older adults with type 1 or type 2 diabetes who also have additional chronic conditions.

  Recruiting Emory University · Atlanta, Georgia · NCT07474376

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.